Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 301–400 of 1,041
Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., & Benoît, J.-P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0289 · Cited by 198
“P-glycoprotein is a 170- to 180-kDa broad-spectrum multidrug efflux pump that belongs to a family of ATP-binding cassette transporters (11).”
BackgroundInfluentialLimtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C., & Ambudkar, S. V. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9302-8 · Cited by 208
“This phenomenon is broadly known as the multidrug resistance (MDR) phenotype [1, 2].”
BackgroundLocalization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues
Fetsch, P. A., Abati, A., Litman, T., Morisaki, K., Honjo, Y., Mittal, K., & Bates, S. E. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.024 · Cited by 197
Self-citationChoi, J.-S., Piao, Y.-J., & Kang, K. W. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-0411-x · Cited by 206
Homolya, L., Váradi, A., & Sarkadi, B. (2003) · BioFactors · doi:10.1002/biof.5520170111 · Cited by 208
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
K. Tiwari, A., Sodani, K., Dai, C.-L., R. Ashby, C., & Chen, Z.-S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795164048 · Cited by 211
“It is well established that ABC transporters produce MDR in tumor cells by actively effluxing antineoplastic drugs, thereby reducing the intracellular concentration of drugs below the effective cytotoxic threshold [13, 17].”
BackgroundP-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers
Seelig, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576559 · Cited by 199
The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma
Das, P. K., Islam, F., & Lam, A. K. (2020) · Cells · doi:10.3390/cells9061392 · Cited by 210
“For example, mutations in key signalling pathway molecules, the increased expression of anti-apoptotic proteins, the presence of quiescent and/or resistant tumour cells or the over-activation of drug efflux pumps are all potential causes of therapy failure [4,5].”
Intracellular Self‐Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance
Yuan, Y., Wang, L., Du, W., Ding, Z., Zhang, J., Han, T., An, L., Zhang, H., & Liang, G. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504329 · Cited by 209
Drugs and their molecular targets: an updated overview
Landry, Y., & Gies, J. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00548.x · Cited by 208
Hojjat-Farsangi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813768 · Cited by 203
“Moreover, alteration in drugs after administration, including drug inactivation, increased rates of drug efflux, changes in drug metabolism [155] and alteration of the local tumor microenvironment [156], all of which have also been identified as important factors in increasing the rate of drug resistance.”
BackgroundVellinga, T. T., Borovski, T., de Boer, V. C. J., Fatrai, S., van Schelven, S., Trumpi, K., Verheem, A., Snoeren, N., Emmink, B. L., Koster, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2290 · Cited by 203
“Furthermore, chemotherapy-induced DNA damage greatly increases the ATP demand (32).”
BackgroundInfluentialCell-Culture Models of the Blood–Brain Barrier
He, Y., Yao, Y., Tsirka, S. E., & Cao, Y. (2014) · Stroke · doi:10.1161/strokeaha.114.005427 · Cited by 194
“Because many anticancer drugs are substrates of these transporters,(59,65) the access of these drugs to CNS tissue or tumors is limited, making patients resistant to anticancer drug treatment, a phenomenon known as multidrug resistance.(65) In contrast to tumor cells, lower expression of these transporters was found i…”
BackgroundNanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers
Cojocaru, F.-D., Botezat, D., Gardikiotis, I., Uritu, C.-M., Dodi, G., Trandafir, L., Rezus, C., Rezus, E., Tamba, B.-I., & Mihai, C.-T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020171 · Cited by 206
“The second is the ATP-binding cassette (ABC) efflux transporter family represented by permeability glycoprotein (P-gp), breast cancer resistance protein (BCRP) and the multidrug resistance associated proteins (MRPs) [103] [104] [105] .”
BackgroundAronica, E., Gorter, J. A., Ramkema, M., Redeker, S., Özbas‐Gerçeker, F., Van Vliet, E. A., Scheffer, G. L., Scheper, R. J., Van Der Valk, P., Baayen, J. C., et al. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.57703.x · Cited by 201
“Resistance to pharmacologic treatment with a broad range of AEDs with different mechanisms of action, but common physical characteristics, supports the involvement of nonspecific mechanisms responsible for different types of clinical drug resistance (for example, as seen with drug resistance to cytostatic drugs in can…”
BackgroundPolymer genomics: An insight into pharmacology and toxicology of nanomedicines☆
KABANOV, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.019 · Cited by 204
“Of equal importance are studies of cellular responses to drugs, particularly, in cancer chemotherapy and other areas where biological agents can select for genetic mutations that result in acquired resistance to these agents [3].”
BackgroundWang, C., Wu, C., Zhou, X., Han, T., Xin, X., Wu, J., Zhang, J., & Guo, S. (2013) · Scientific Reports · doi:10.1038/srep02852 · Cited by 206
The human ATP‐binding cassette (ABC) transporter superfamily
Dean, M., Moitra, K., & Allikmets, R. (2022) · Human Mutation · doi:10.1002/humu.24418 · Cited by 187
“The intensively studied multidrug resistance protein, P‐ glycoprotein, ABCB1/PGP is a full transporter playing an essential role in xenobiotic removal, regulation of the blood, brain, and other tissue barriers and is amplified in many chemotherapy drug‐resistant cell lines (Borst, 1999; Childs & Ling, 1994; Gottesman…”
BackgroundWang, L., Sun, Q., Wang, X., Wen, T., Yin, J.-J., Wang, P., Bai, R., Zhang, X.-Q., Zhang, L.-H., Lu, A.-H., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511560b · Cited by 204
Hazlehurst, L. A., Landowski, T. H., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206943 · Cited by 203
“These mechanisms include decreased drug uptake, increased drug efflux, alterations in the drug target, drug metabolism, repair of DNA damage, cell cycle checkpoint mediators, and changes in down- stream mediators of the apoptotic pathway (Dalton and Salmon, 1992; Gottesman et al., 2002) (Figure 1).”
BackgroundAdvances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update
Castillo, R. R., Lozano, D., González, B., Manzano, M., Izquierdo-Barba, I., & Vallet-Regí, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598375 · Cited by 197
“ATP is also found to be upregulated in cancerous tissues and in processes such as chemoresitance and uncontrolled tumor growth, hence making possible to exploit differences between normal and cancer cells [137,138].”
BackgroundModulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
Nieth, C., Priebsch, A., Stege, A., & Lage, H. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00523-4 · Cited by 200
Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment
Kang, L., Gao, Z., Huang, W., Jin, M., & Wang, Q. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.03.001 · Cited by 195
Isolation and characterization of cancer stem like cells in human glioblastoma cell lines
Qiang, L., Yang, Y., Ma, Y.-J., Chen, F.-H., Zhang, L.-B., Liu, W., Qi, Q., Lu, N., Tao, L., Wang, X.-T., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.016 · Cited by 196
“It has been shown that various types of ATP-binding cassette (ABC) transporters, including those encoded by the multidrugresistant (MDR) gene 1, the MDR protein (MRP), and the breast cancer-resistant protein 1 (BCRP1/ ABCG2), contribute to drug resistance in many cancers by pumping the drugs out of the cells, and it i…”
Heffeter, P., Pape, V. F. S., Enyedy, É. A., Keppler, B. K., Szakacs, G., & Kowol, C. R. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7487 · Cited by 202
“A frequently observed problem is the occurrence of multi-drug resistance (MDR), when cells become cross-resistant to multiple structurally and mechanistically unrelated drugs (57).”
InfluentialJames, C. E., & Davey, M. W. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2008.06.009 · Cited by 200
Tal, N., & Schuldiner, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902400106 · Cited by 195
Exploration of Fluorine Chemistry at the Multidisciplinary Interface of Chemistry and Biology
Ojima, I. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400301u · Cited by 198
ATP-binding cassette (ABC) transporters in normal and pathological lung
van der Deen, M., de Vries, E. G., Timens, W., Scheper, R. J., Timmer-Bosscha, H., & Postma, D. S. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-59 · Cited by 198
“It transports many hydrophobic substrates and anti-cancer drugs including etoposide, doxorubicin and vinblastine (for review, see [11]) and is mainly apically expressed in organs involved in excretion such as liver and intestine.”
A Tailored DNA Nanoplatform for Synergistic RNAi‐/Chemotherapy of Multidrug‐Resistant Tumors
Liu, J., Song, L., Liu, S., Zhao, S., Jiang, Q., & Ding, B. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201809452 · Cited by 203
Yasuda, H. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.04.026 · Cited by 198
Diverse Molecular Targets for Chalcones with Varied Bioactivities
Zhou, B. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000291 · Cited by 195
“Other proteins ABC transporters: ATP-binding cassette (ABC) transporters, such as p-glycoprotein (P-gp) and breast cancer resistant protein (BCRP), are a group of efflux pumps capable of transporting drugs out of the cells, whose overexpression are critical in conferring multi-drug resistance (MDR) in many cancer cell…”
BackgroundMolecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197
Malek, E., Jagannathan, S., & Driscoll, J. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2469 · Cited by 195
“Drug resistance, either de novo or acquired, still accounts for the majority of tumor relapses contributing to poor outcomes [6–10].”
BackgroundCancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Nadali Hezaveh, M., Khosravi, S., Kamali Andani, M., Cordani, M., Basiri, M., & Ghavami, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176013 · Cited by 184
3D printed nanocomposite matrix for the study of breast cancer bone metastasis
Zhu, W., Holmes, B., Glazer, R. I., & Zhang, L. G. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.010 · Cited by 193
Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer Agents
Rao, P. V., Nallappan, D., Madhavi, K., Rahman, S., Jun Wei, L., & Gan, S. H. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3685671 · Cited by 192
Regulation of multidrug resistance by microRNAs in anti-cancer therapy
An, X., Sarmiento, C., Tan, T., & Zhu, H. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.002 · Cited by 194
Giovannetti, E., Erozenci, A., Smit, J., Danesi, R., & Peters, G. J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.03.010 · Cited by 192
“The most common reason for the acquisition of esistance to a broad range of anticancer drugs is expresion of one or more energy-dependent transporters that etect and eject anticancer drugs from cells, resulting in ultidrug resistance (MDR) [2].”
BackgroundInfluential5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry
Kaminskyy, D., Kryshchyshyn, A., & Lesyk, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.031 · Cited by 184
Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1
Alam, A., Küng, R., Kowal, J., McLeod, R. A., Tremp, N., Broude, E. V., Roninson, I. B., Stahlberg, H., & Locher, K. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717044115 · Cited by 187
Epirubicin-Adsorbed Nanodiamonds Kill Chemoresistant Hepatic Cancer Stem Cells
Wang, X., Low, X. C., Hou, W., Abdullah, L. N., Toh, T. B., Mohd Abdul Rashid, M., Ho, D., & Chow, E. K.-H. (2014) · ACS Nano · doi:10.1021/nn503491e · Cited by 193
“20 Specific inhibitors, however, may lead to ineffectiveness where multiple ABC transporters coexpress andconfer chemoresistance in tumors.(21)”
Xiao, Q., Zhao, W., Wu, C., Wang, X., Chen, J., Shi, X., Sha, S., Li, J., Liang, X., Yang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105274 · Cited by 188
Flahaut, M., Meier, R., Coulon, A., Nardou, K. A., Niggli, F. K., Martinet, D., Beckmann, J. S., Joseph, J.-M., Mühlethaler-Mottet, A., & Gross, N. (2009) · Oncogene · doi:10.1038/onc.2009.80 · Cited by 190
“The latter is already known for its role in conferring chemoresistance in cancers (Gottesman et al., 2002; Modok et al., 2006).”
BackgroundInfluentialSills, G. J., Mohanraj, R., Butler, E., McCrindle, S., Collier, L., Wilson, E. A., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.46304.x · Cited by 194
Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery
Raemdonck, K., Braeckmans, K., Demeester, J., & De Smedt, S. C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60299k · Cited by 188
Modelling three-dimensional protein structures for applications in drug design
Schmidt, T., Bergner, A., & Schwede, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.027 · Cited by 187
“In many cancer cell types, upregulation of MDR1 activity causes fast removal of drugs, triggering multidrug resistance [78].”
BackgroundmiR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer
Karaayvaz, M., Zhai, H., & Ju, J. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.193 · Cited by 191
“One major resistance mechanism utilized by tumor cells is to resist drug-induced cell death through disruptions of apoptotic pathways.(6) Thus, it is essential to better understand the mechanisms of drug resistance and to discover novel strategies to further improve the effectiveness of 5-FU.”
BackgroundDesale, K., Kuche, K., & Jain, S. (2021) · Biomaterials Science · doi:10.1039/d0bm01755h · Cited by 182
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
Xue, X., & Liang, X.-J. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10326 · Cited by 187
Seo, S., Hatano, E., Higashi, T., Hara, T., Tada, M., Tamaki, N., Iwaisako, K., Ikai, I., & Uemoto, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1357 · Cited by 191
Cooperativity Principles in Self-Assembled Nanomedicine
Li, Y., Wang, Y., Huang, G., & Gao, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00195 · Cited by 191
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases
Candeil, L., Gourdier, I., Peyron, D., Vezzio, N., Copois, V., Bibeau, F., Orsetti, B., Scheffer, G. L., Ychou, M., Khan, Q. A., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20032 · Cited by 180
Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308559200 · Cited by 181
Statins and cancer: Current and future prospects
Osmak, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.011 · Cited by 189
“MDR is based on the active export of drugs caused by the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein and MDR-associated proteins [97].”
BackgroundSucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues
Schiffman, S. S., & Rother, K. I. (2013) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2013.842523 · Cited by 180
“…alkaloids (vinblastine and vincristine) is associated with multidrug resistance; that is, elevated P-gp efflux may reduce intracellular concentrations of therapeutic drugs in neoplastic tissues (Gottesman and Pastan, 1988; Endicott and Ling, 1989; Mechetner et al., 1998; Gottesman et al., 2002).”
BackgroundDrugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
“Cellular overproduction of P-glycoprotein (P-gp), which acts as an efflux pump for various anticancer drugs (e.g. anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and some of the newer antitumor drugs) is one of the more relevant mechanisms underlying MDR. P-gp belongs to the superfamily of ATP-binding c…”
BackgroundInfluentialHyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance
Toole, B. P., & Slomiany, M. G. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.04.002 · Cited by 182
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases
Chowdhury, A., Kunjiappan, S., Panneerselvam, T., Somasundaram, B., & Bhattacharjee, C. (2017) · International Nano Letters · doi:10.1007/s40089-017-0208-0 · Cited by 183
Jo, Y., Choi, N., Kim, K., Koo, H.-J., Choi, J., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 183
“HIF-1 mediated enhancement of drug efflux Decreased intracellular concentration of drugs [61, 62]”
BackgroundFunctionalized liposomes for targeted breast cancer drug delivery
Nel, J., Elkhoury, K., Velot, É., Bianchi, A., Acherar, S., Francius, G., Tamayol, A., Grandemange, S., & Arab-Tehrany, E. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.027 · Cited by 182
Drug interactions at the blood-brain barrier: Fact or fantasy?☆
Eyal, S., Hsiao, P., & Unadkat, J. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.017 · Cited by 186
“In general, little toxicity to the central nervous system has been reported in patients treated with P-gp inhibitors, even in those treated with neurotoxic chemotherapeutic compounds (Gottesman et al., 2002).”
Mesoporous carbon nanomaterials in drug delivery and biomedical application
Zhao, Q., Lin, Y., Han, N., Li, X., Geng, H., Wang, X., Cui, Y., & Wang, S. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1399300 · Cited by 185
“The distribution of conventional chemo-drugs is usually lack of specificity after administration which would severely limit their treatment efficacy, cause side effects and induce the multi-drug resistance (MDR) (Kartner et al., 1983; Thiebaut et al., 1987; Boesch et al., 1991; Kane, 1996; Gottesman et al., 2002; Gant…”
BackgroundInfluentialNovel delivery approaches for cancer therapeutics
Mitra, A. K., Agrahari, V., Mandal, A., Cholkar, K., Natarajan, C., Shah, S., Joseph, M., Trinh, H. M., Vaishya, R., Yang, X., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.067 · Cited by 183
“MDR is a phenomenon where tumor cells develop resistance to functionally and structurally unrelated anticancer drugs [329].”
A Distinct Subset of Self-Renewing Human Memory CD8+ T Cells Survives Cytotoxic Chemotherapy
Turtle, C. J., Swanson, H. M., Fujii, N., Estey, E. H., & Riddell, S. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.015 · Cited by 179
“…chemotherapy are related both to cell quiescence and the overexpression of ATP-binding cassette (ABC)-superfamily multidrug efflux proteins that protect cells from toxic xenobiotics and endogenous metabolites (Chaudhary and Roninson, 1991; Gottesman et al., 2002; Mizutani et al., 2008).”
InfluentialTumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
Michael, M., & Doherty, M. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.120 · Cited by 177
Waltzing transporters and 'the dance macabre' between humans and bacteria
Lomovskaya, O., Zgurskaya, H. I., Totrov, M., & Watkins, W. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2200 · Cited by 183
“The very first MDR transporter to be discovered, human P-glycoprotein (P-gp”
BackgroundTian, G., Zheng, X., Zhang, X., Yin, W., Yu, J., Wang, D., Zhang, Z., Yang, X., Gu, Z., & Zhao, Y. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.11.022 · Cited by 182
Masuda, S., & Inui, K.-I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.006 · Cited by 184
Zhou, H., Wu, S., Zhai, S., Liu, A., Sun, Y., Li, R., Zhang, Y., Ekins, S., Swaan, P. W., Fang, B., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7012024 · Cited by 179
Kelly, R. J., Draper, D., Chen, C. C., Robey, R. W., Figg, W. D., Piekarz, R. L., Chen, X., Gardner, E. R., Balis, F. M., Venkatesan, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1725 · Cited by 172
“Pgp, encoded by the MDR-1 (ABCB1) gene, is an energy-dependent efflux pump that lowers the intracellular concentrations of many chemotherapeutic agents (1, 2).”
Self-citationKannan, P., Telu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Halldin, C., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn100078a · Cited by 181
“Keywords: Positron emission tomography, drug transporters, P-glycoprotein, breast cancer resistance protein, blood-brain barrier, transport inhibitors, tariquidar E fflux transporters belonging to the ATP-binding cassette (ABC) family, which are highly expressed at the blood-brain barrier (BBB), prevent the entry of d…”
BackgroundSelf-citationIdentification and targeting of cancer stem cells
Schatton, T., Frank, N. Y., & Frank, M. H. (2009) · BioEssays · doi:10.1002/bies.200900058 · Cited by 174
“The effectiveness of cancer therapy as a strategy to cure metastatic or disseminated malignant disease is frequently impaired by either intrinsic or acquired tumor resistance to cytotoxic agents or ionizing radiation.((60)) Cellular mechanisms of therapeutic resistance include increased DNA damage recognition and repa…”
BackgroundStructural basis for gating mechanisms of a eukaryotic P-glycoprotein homolog
Kodan, A., Yamaguchi, T., Nakatsu, T., Sakiyama, K., Hipolito, C. J., Fujioka, A., Hirokane, R., Ikeguchi, K., Watanabe, B., Hiratake, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321562111 · Cited by 178
Lipid-coated polymeric nanoparticles for cancer drug delivery
Krishnamurthy, S., Vaiyapuri, R., Zhang, L., & Chan, J. M. (2015) · Biomaterials Science · doi:10.1039/c4bm00427b · Cited by 181
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2106) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 177
“Redox resetting has been implicated in drug resistance at multiple levels, including elevated drug efflux, altered drug metabolism and mutated drug targets [10, 11].”
BackgroundEvolutionary Conservation of Vertebrate Blood–Brain Barrier Chemoprotective Mechanisms in Drosophila
Mayer, F., Mayer, N., Chinn, L., Pinsonneault, R. L., Kroetz, D., & Bainton, R. J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5564-08.2009 · Cited by 182
“For example, in vertebrates, MDR1/Pgp overexpression specifically promotes chemotheraptic drug resistance in cancer cells (Gottesman et al., 2002).”
BackgroundCastillo, R. R., Colilla, M., & Vallet-Regí, M. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1211637 · Cited by 176
“The Pgp is usually highly expressed in difficult-to-treat cancers such as stomach, breast and pancreas carcinomas; unfortunately it is also quite common in other metastatic tumors, and when highly expressed, it induces drug resistance through drug drainage efflux out of the cell.”
BackgroundInfluentialAbdal Dayem, A., Choi, H., Yang, G.-M., Kim, K., Saha, S., & Cho, S.-G. (2016) · Nutrients · doi:10.3390/nu8090581 · Cited by 172
“ABC transporters are involved in drug efflux, thereby decreasing in intracellular concentrations [293].”
BackgroundBreaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics
Fan, W., Tang, W., Lau, J., Shen, Z., Xie, J., Shi, J., & Chen, X. (2019) · Advanced Materials · doi:10.1002/adma.201806381 · Cited by 182
Cao, N., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.05.016 · Cited by 179
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
“3.1 The role of ABC transporters in MDR Expression of some of the ABC transporters has been linked to development of MDR in cancer cells (Gottesman et al., 2002).”
BackgroundInfluentialNatural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer
Joshi, P., Vishwakarma, R. A., & Bharate, S. B. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.047 · Cited by 174
Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue
Gote, V., Nookala, A. R., Bolla, P. K., & Pal, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094673 · Cited by 166
“BCRP is a half-transporter composed of N-terminal NBD and a carboxy-terminal TMD containing six membrane-spanning helices [44,45].”
BackgroundHaber, M., Smith, J., Bordow, S. B., Flemming, C., Cohn, S. L., London, W. B., Marshall, G. M., & Norris, M. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6196 · Cited by 177
Doublier, S., Belisario, D. C., Polimeni, M., Annaratone, L., Riganti, C., Allia, E., Ghigo, D., Bosia, A., & Sapino, A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-4 · Cited by 178
“MDR may be either constitutive or acquired and can be mediated by several different mechanisms including target alterations, enhanced DNA repair, evasion of apoptosis, induction of drug-metabolizing enzymes, alterations in drug uptake and active transport of drugs out of cells [9].”
BackgroundBiological and related applications of pillar[n]arenes
Sathiyajith, C., Shaikh, R. R., Han, Q., Zhang, Y., Meguellati, K., & Yang, Y.-W. (2017) · Chemical Communications · doi:10.1039/c6cc08967d · Cited by 176
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., & Ma, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637675 · Cited by 168
Feng, S., Lu, J., Wang, K., Di, D., Shi, Z., Zhao, Q., & Wang, S. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134886 · Cited by 179
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“Drug efflux transporters are more prevalent in drug-resistant tumor cells, which actively pump chemotherapeutic drugs out of the cell [36].”
BackgroundHypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
Akman, M., Belisario, D. C., Salaroglio, I. C., Kopecka, J., Donadelli, M., De Smaele, E., & Riganti, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01824-3 · Cited by 174
“In hypoxic cells, the ER stress sensors are activated and cooperate in inducing chemoresistance. glucose-regulated protein 78 (GRP78) increases the anti-apoptotic Bcl-2/Bax ratio and transcriptionally induces ABC transporter B1/multidrug resistance 1 (ABCB1/MDR1) gene by activating Janus kinase (JNK).”
BackgroundInfluentialThe Genetics of ATP‐Binding Cassette Transporters
Dean, M. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)00024-8 · Cited by 174
EmrE, a model for studying evolution and mechanism of ion-coupled transporters
Schuldiner, S. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.12.018 · Cited by 164
“This resistance presents a serious problem in the treatment of infectious diseases and cancer and the clinical implications have been reviewed elsewhere [1,2].”
BackgroundIntegrated Hollow Mesoporous Silica Nanoparticles for Target Drug/siRNA Co‐Delivery
Ma, X., Zhao, Y., Ng, K. W., & Zhao, Y. (2013) · Chemistry – A European Journal · doi:10.1002/chem.201302736 · Cited by 176
Spudich, A., Kilic, E., Xing, H., Kilic, Ü., Rentsch, K. M., Wunderli-Allenspach, H., Bassetti, C. L., & Hermann, D. M. (2006) · Nature Neuroscience · doi:10.1038/nn1676 · Cited by 174
Nath, S., Daneshvar, K., Roy, L. D., Grover, P., Kidiyoor, A., Mosley, L., Sahraei, M., & Mukherjee, P. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.16 · Cited by 168
Ludwig, J. A., Szakács, G., Martin, S. E., Chu, B. F., Cardarelli, C., Sauna, Z. E., Caplen, N. J., Fales, H. M., Ambudkar, S. V., Weinstein, J. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3322 · Cited by 176
“May 1, 2006 also intrinsically express P-gp (11, 39 ).”
BackgroundSelf-citationChemoresistance in solid tumours
Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl280 · Cited by 170
“Increases in drug efflux are often responsible for enhanced drug resistance and are frequently due to enhanced expression of ATP binding cassette (ABC) transporter proteins, such as P-glycoprotein (Pgp) [3].”
Background
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.